In a groundbreaking move towards advancing breast cancer diagnostics, Hologic and Bayer have joined forces to promote contrast-enhanced mammography (CEM) across Asia Pacific, Canada, and Europe. This innovative approach involves the intravenous administration of iodinated contrast, coupled with the utilization of both low-energy and high-energy X-rays, similar to digital mammography. The iodine selectively absorbs high-energy X-rays, potentially enhancing the accuracy of cancer detection.
Bayer, a leader in healthcare solutions, is the provider of CEM-approved injectable systems, while Hologic, renowned for their cutting-edge medical imaging technology, offers a state-of-the-art 3D mammography system that seamlessly integrates with CEM. This collaboration is poised to revolutionize breast cancer diagnosis by streamlining the adoption of CEM through a comprehensive product bundle and extensive training programs.
Since GE HealthCare's acquisition of 510(k) clearance for its inaugural CEM system in 2011, evidence supporting its superior sensitivity, particularly in cases of dense breast tissue, has led to a surge in adoption. Advocates assert that CEM outpaces MRI in confirming cancer diagnoses for patients at intermediate and high-risk levels, thereby freeing up critical imaging resources for other patients.
Notably, Hologic, a significant contributor to the United Kingdom's healthcare infrastructure, supplied a third of the nation's mammography machines in the previous year. Their strategic alliance with Bayer, a distinguished manufacturer of injectable equipment approved for the CEM process, represents a major milestone in promoting this cutting-edge diagnostic technology.
Over recent years, contrast-enhanced mammography has garnered widespread acclaim as a diagnostic tool of unparalleled precision. Tanja Brycker, Vice President of Strategic Development for Breast and Skeletal Health and GYN Solutions at Hologic, emphasized that the collaboration with Bayer will empower healthcare professionals worldwide to incorporate CEM into their breast cancer diagnosis protocols.
While the benefits of CEM are undeniable, it's essential to acknowledge the associated costs and training requirements. Upgrading existing mammography machines for CEM can range from $49,000 to $110,000, and staff members may necessitate training and support in areas such as contrast agent administration, cannulation techniques, theeration of powered injection pumps, and managing rare allergic reactions. Despite these considerations, the potential for early and more accurate breast cancer detection provided by CEM is a monumental step forward in the fight against this pervasive disease.
This innovative approach holds immense promise for patients and healthcare professionals alike, heralding a new era in breast cancer diagnosis.
